A drug that was trialled in Portsmouth and can prolong the lives of breast cancer sufferers by nearly six months has been refused by the NHS because of costs.The Herceptin type drug was trialled in Portsmouth but can cost up to £90,000 per patient.
We speak to National Institute for Health and Care Excellence's Andrew Dillion about the new drug and what he thinks about the NHS' decision to refuse the expensive treatment.
The watchdog, which decides which new medicines are cost effective, said its guidance for Kadcyla, manufactured by Roche, or trastuzumab emtansine, was in draft form and is now up for public consultation.
Meanwhile patients will be able to apply to their local NHS and to the Cancer Drugs Fund.
More top news
Friday night's forecast for the east of the region
Friday night's forecast for the west of the region
Simon's Blog - The Sands Of Time